慢性髓系白血病病期演变时CD_(34)抗原表达及其临床意义

Expression and clinical significant of CD_(34) antigen in developing chronic myeloid leukemia

目的 检测 CD34抗原在慢性髓系白血病 (CML)不同病期中的表达 ,并探讨其与临床化疗疗效及预后的关系。方法 采用流式细胞术检测 CML患者外周血和 (或 )骨髓单个核细胞(MNC) CD34抗原及 P1 70 糖蛋白的表达。结果 CML慢性期、加速期、急变期外周血 MNC CD34抗原阳性率比较差异有非常显著性 (P <0 .0 0 1) ,随着治疗的有效 CD34阳性率下降 ;P1 70 阴性组与 P1 70 阳性组 CD34阳性率比较差异有非常显著性 (P <0 .0 1) ,治疗有效率比较差异有差异性 (P <0 .0 5 )。结论 CML慢性期患者 CD34抗原表达与临床疗效呈负相关 ,对预测患者进入急变期有一定临床意义 ;CML病期演变时 CD34阳性白血病细胞 P1 70

Objective To investigate the expressions of CD 34 antigen in chronic myeloid leukenmia(CML) at different stages and the relationship between the expression of CD 34 antigen and efficacy of chemotherapy.Methods Fluorescence flow cytometry was used to measure the expressions of CD 34 antigen and P-glycoprotein(P 170 ) at the surface of mononuclear cells (MNC)in peripheral blood and/or bone marrow in CML patients.Results The positive rates of MNC CD 34 antigen in CML patients at chronic, accelerative and blastic stages had significant differences(P<0.001),decreasing with effective therapy. Both the positive rate and efficient rate between P 170 -negative group and P 170 positive group were different significantly(P<0.05).Conclusion Expression of CD 34 antigen in CML patients at chronic stage is negatirely correlated to clinical efficacy,having clinical significants for prediction of the development of CML. High level of P 170 expression in CD 34 + leukemia cells might be responsible for chemotherapeutic drug resistance in developing CML. [